Skip to main content
SpringerLink
Log in

Obinutuzumab in multidrug-resistant hairy cell leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Robak T, Matutes E, Catovsky D et al (2015) Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v100–v107

    Article  PubMed  Google Scholar 

  2. Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110

    Article  PubMed  CAS  Google Scholar 

  3. Sehn LH, Chua NS, Mayer J (2015) GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared to bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphomas. J Clin Oncol 33(Supplement):LBA8502

    Google Scholar 

  4. Freeman CL, Dixon M, Houghton R (2014) Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: analysis of the CLL11 study dataset. Blood 124(Supplement):3339

    Google Scholar 

  5. Ginaldi L, De MM, Matutes E et al (1998) Levels of expression of CD19 and CD20 in chronic B-cell leukaemias. J Clin Pathol 51:364–369

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Funding

This work was not supported by any grants.

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, Medical University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria

    Jan-Paul Bohn, Ella Willenbacher & Michael Steurer

Authors
  1. Jan-Paul Bohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ella Willenbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Steurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan-Paul Bohn.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from the patient for publication of this case report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bohn, JP., Willenbacher, E. & Steurer, M. Obinutuzumab in multidrug-resistant hairy cell leukemia. Ann Hematol 95, 351–352 (2016). https://doi.org/10.1007/s00277-015-2520-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2520-y

Keywords

Search

Navigation